erytromycine
      J - Antiinfectives For Systemic Use -> J01 - Antibacterials For Systemic Use -> J01F - Macrolides, Lincosamides And Streptogramins -> J01FA - Macrolides -> J01FA01 - Erythromycin
    
          
        Administration category:
         Free
      
    
          
        Medicine group:
        antibacterial
      
    
    
      Safety margins
| Weight | ROA | Dosage | 
|---|---|---|
| ROA: po | Dosage: min. 250mg 4 dd to max. 1000mg 4 dd | |
| ROA: iv | Dosage: min. 250mg 4 dd to max. 1000mg 4 dd | 
Dosage for "I" sensitivity
| Weight | ROA | Load | Dosage | 
|---|---|---|---|
| ROA: po | Load: - | Dosage: 1000mg 4 dd | |
| ROA: iv | Load: - | Dosage: 1000mg 4 dd | 
Kidney function
              
                Renal elimination: 
                2-15%
              
            
                    
                                
              
                Dosage: 
                independent on kidney function
              
            
                    
        Interactions
| Interaction with (ATC): | Expected effect: | 
|---|---|
| Interaction with (ATC): N03AF01 - Carbamazepine | Expected effect: verhoging plasmaconcentratie carbamazepine | 
| Interaction with (ATC): L04AD01 - Ciclosporin | Expected effect: verhoging concentratie ciclosporine | 
| Interaction with (ATC): L04AD02 - Tacrolimus | Expected effect: verhoging concentratie tacrolimus | 
| Interaction with (ATC): L04AA10 - Sirolimus | Expected effect: verhoging concentratie sirolimus | 
| Interaction with (ATC): R06AX12 - Terfenadine | Expected effect: toename cardiotoxiciteit | 
| Interaction with (ATC): A03FA02 - Cisapride | Expected effect: toename cardiotoxiciteit | 
| Interaction with (ATC): C01BA03 - Disopyramide | Expected effect: toename cardiotoxiciteit | 
| Interaction with (ATC): C01AA05 - Digoxin | Expected effect: verhoging plasmaconcentratie digoxine | 
| Interaction with (ATC): R03DA04 - Theophylline | Expected effect: verhoging plasmaconcentratie theofylline | 
| Interaction with (ATC): J05AE - Protease Inhibitors | Expected effect: verhoging plasmaconcentratie erytromycine | 
Pregnancy
Due to the expiration of the alphanumeric classification for use in pregnancy and lactation, reference is made to the current, online information of the Teratology Information Service (TIS) of LAREB:
- http://www.lareb.nl//Teratologie/Naslagwerk-GZB/GZB---Zwangerschap#TOC_Middelen_bij6
- http://www.lareb.nl//Teratologie/Naslagwerk-GZB/GZB---Borstvoeding#TOC_Middelen_bij16
          
            For individual advice, consult an expert on site.          
        
      Metadata
            Swab vid: M-1388.2
            Updated: 05/23/2024 - 15:35
            Status: Published
          
